HEMOSTEMIX INC (HEM.CA) Stock Price, Quote, News and Overview
TSX-V:HEM - TSX Venture Exchange - CA4236943060 - Common Stock - Currency: CAD
HEM.CA Quote, Performance and Key Statistics
TSX-V:HEM (2/21/2025, 7:00:00 PM)
0.175
-0.02 (-7.89%)
The current stock price of HEM.CA is 0.175 CAD. In the past month the price decreased by -50%. In the past year, price increased by 118.75%.
HEM.CA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| FRX.CA | FENNEC PHARMACEUTICALS INC | N/A | 261.54M | ||
| EPRX.CA | EUPRAXIA PHARMACEUTICALS INC | N/A | 188.23M | ||
| EDT.CA | SPECTRAL MEDICAL INC | N/A | 185.09M | ||
| TH.CA | THERATECHNOLOGIES INC | N/A | 121.39M | ||
| MDNA.CA | MEDICENNA THERAPEUTICS CORP | N/A | 89.95M | ||
| ONC.CA | ONCOLYTICS BIOTECH INC | N/A | 82.42M | ||
| MSCL.CA | SATELLOS BIOSCIENCE INC | N/A | 78.27M | ||
| COV.CA | COVALON TECHNOLOGIES LTD | 25.45 | 76.72M | ||
| MBX.CA | MICROBIX BIOSYSTEMS INC | 48.5 | 65.22M | ||
| MDCX.CA | MEDICUS PHARMA LTD | N/A | 61.74M | ||
| SVA.CA | SERNOVA BIOTHERAPEUTICS INC | N/A | 52.45M | ||
| HBP.CA | HELIX BIOPHARMA CORP | N/A | 51.96M |
Related stock screener links
About HEM.CA
Company Profile
Hemostemix, Inc. is a clinical-stage biotechnology company, which is focused on developing and commercializing a proprietary autologous cell therapy to treat ischemic diseases. The company is headquartered in Calgary, Alberta. The company went IPO on 2012-12-20. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. The company is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The firm is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.
Company Info
HEMOSTEMIX INC
707 7th Ave. SW, Suite 1150
Calgary ALBERTA T2P 3H6 CA
CEO: Thomas Smeenk
Employees: 9
Company Website: https://hemostemix.com/
Investor Relations: http://hemostemix.com/investor-overview/
Phone: 19055804170
HEMOSTEMIX INC / HEM.CA FAQ
What is the stock price of HEMOSTEMIX INC today?
The current stock price of HEM.CA is 0.175 CAD. The price decreased by -7.89% in the last trading session.
What is the ticker symbol for HEMOSTEMIX INC stock?
The exchange symbol of HEMOSTEMIX INC is HEM and it is listed on the TSX Venture Exchange exchange.
On which exchange is HEM.CA stock listed?
HEM.CA stock is listed on the TSX Venture Exchange exchange.
What is HEMOSTEMIX INC worth?
HEMOSTEMIX INC (HEM.CA) has a market capitalization of 25.50M CAD. This makes HEM.CA a Nano Cap stock.
How many employees does HEMOSTEMIX INC have?
HEMOSTEMIX INC (HEM.CA) currently has 9 employees.
What are the support and resistance levels for HEMOSTEMIX INC (HEM.CA) stock?
HEMOSTEMIX INC (HEM.CA) has a support level at 0.07 and a resistance level at 0.2. Check the full technical report for a detailed analysis of HEM.CA support and resistance levels.
Should I buy HEMOSTEMIX INC (HEM.CA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of HEM.CA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of HEM.CA, evaluating the profitability, health, valuation and growth aspects
- HEMOSTEMIX INC (HEM.CA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- HEMOSTEMIX INC (HEM.CA) Sales and EPS estimates to see what analysts future expectations are.
- HEMOSTEMIX INC (HEM.CA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- HEMOSTEMIX INC (HEM.CA) Insider and Institutional Ownership to learn about the owners and their transactions.
- HEMOSTEMIX INC (HEM.CA) Stock Chart to make your own analysis
- HEMOSTEMIX INC (HEM.CA) Latest news and press-releases to stay up to date.
Does HEMOSTEMIX INC (HEM.CA) stock pay dividends?
HEM.CA does not pay a dividend.
When does HEMOSTEMIX INC (HEM.CA) report earnings?
HEMOSTEMIX INC (HEM.CA) will report earnings on 2025-04-28.
What is the Price/Earnings (PE) ratio of HEMOSTEMIX INC (HEM.CA)?
HEMOSTEMIX INC (HEM.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.02).
HEM.CA Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to HEM.CA. When comparing the yearly performance of all stocks, HEM.CA is one of the better performing stocks in the market, outperforming 96.54% of all stocks.
HEM.CA Financial Highlights
Over the last trailing twelve months HEM.CA reported a non-GAAP Earnings per Share(EPS) of -0.02. The EPS increased by 48.52% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -1258.94% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
HEM.CA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to HEM.CA. The Buy consensus is the average rating of analysts ratings from 9 analysts.